{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:29:14Z","timestamp":1787243354150,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peritoneal metastases (PM) are common in small bowel neuroendocrine tumors (SBNETs). Risk factors for PM and their impact on disease prognosis is poorly studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study reviews 20 years of experience with SBNETs, focusing on identifying risk factors for PM and the long-term oncologic outcomes of cytoreduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective single institutional study was performed from 2005 to 2024 identifying patients with SBNETs who underwent operative resection of their tumors. Primary endpoints were overall survival and progression-free survival, assessed with the Kaplan\u2013Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 396 patients were included in the study with rates of metastatic disease and PM of 71.7 and 30.1%, respectively. The presence of liver metastases, female sex, higher T stage, and elevated pancreastatin levels were associated with an increased risk of PM. By Kaplan\u2013Meier analysis, patients with PM had worse overall survival (109 vs. 169 months;\n                      <jats:italic>p\u2009<\/jats:italic>\n                      =\u20090.01) and progression-free survival (42 vs. 75 months,\n                      <jats:italic>p\u2009<\/jats:italic>\n                      &lt;0\u2009.01) than those without PM; however, on multivariable analysis, these were not significant. Patients who received cytoreduction of PM had higher rates of major complications (i.e. Clavien\u2013Dindo 3 or 4) than those who did not. Additionally, patients with PM had higher rates of postoperative bowel obstruction, although the greater use of peptide receptor radionuclide therapy in this population may also have contributed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Peritoneal metastases are common in SBNET. Aggressive surgical management is associated with favorable long-term survival, which suggests it should be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18374-7","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:01:56Z","timestamp":1758808916000},"page":"265-274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk Factors and Prognosis of Peritoneal Metastases in Small Bowel Neuroendocrine Tumor Patients"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4281-9666","authenticated-orcid":false,"given":"Jeremy","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis C.","family":"Borbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po Hien","family":"Ear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Bellizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"3","key":"18374_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/archsurg.142.3.229","volume":"142","author":"I Hatzaras","year":"2007","unstructured":"Hatzaras I, Palesty JA, Abir F, et al. Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the connecticut tumor registry. Arch Surg. 2007;142(3):229\u201335.","journal-title":"Arch Surg."},{"issue":"Suppl 3","key":"18374_CR2","doi-asserted-by":"publisher","first-page":"S742","DOI":"10.1245\/s10434-015-4620-2","volume":"22","author":"A Pasquer","year":"2015","unstructured":"Pasquer A, Walter T, Hervieu V, et al. Surgical management of small bowel neuroendocrine tumors: specific requirements and their impact on staging and prognosis. Ann Surg Oncol. 2015;22(Suppl 3):S742-749.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"18374_CR3","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1002\/(SICI)1097-0142(19961015)78:8<1686::AID-CNCR8>3.0.CO;2-C","volume":"78","author":"B Vasseur","year":"1996","unstructured":"Vasseur B, Cadiot G, Zins M, et al. Peritoneal carcinomatosis in patients with digestive endocrine tumors. Cancer. 1996;78(8):1686\u201392.","journal-title":"Cancer."},{"issue":"1","key":"18374_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.surg.2020.03.030","volume":"169","author":"SM Wonn","year":"2021","unstructured":"Wonn SM, Limbach KE, Pommier SJ, et al. Outcomes of cytoreductive operations for peritoneal carcinomatosis with or without liver cytoreduction in patients with small bowel neuroendocrine tumors. Surgery. 2021;169(1):168\u201374.","journal-title":"Surgery."},{"issue":"8","key":"18374_CR5","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.1245\/s10434-024-15316-7","volume":"31","author":"H Gudmundsdottir","year":"2024","unstructured":"Gudmundsdottir H, Fogliati A, Grotz TE, et al. Value of surgical cytoreduction in patients with small intestinal neuroendocrine tumors metastatic to the liver and peritoneum. Ann Surg Oncol. 2024;31(8):5370\u20136.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"18374_CR6","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s40618-024-02330-5","volume":"47","author":"M Tsoli","year":"2024","unstructured":"Tsoli M, Wilson H, Armonis P, et al. Peritoneal metastases in patients with neuroendocrine neoplasms: a challenging site of metastases with clinical and prognostic implications. J Endocrinol Invest. 2024;47(9):2295\u2013303.","journal-title":"J Endocrinol Invest."},{"issue":"2","key":"18374_CR7","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s00268-017-4364-1","volume":"42","author":"O Norlen","year":"2018","unstructured":"Norlen O, Montan H, Hellman P, Stalberg P, Sundin A. Preoperative (68)Ga-DOTA-somatostatin analog-PET\/CT hybrid imaging increases detection rate of intra-abdominal small intestinal neuroendocrine tumor lesions. World J Surg. 2018;42(2):498\u2013505.","journal-title":"World J Surg."},{"issue":"2","key":"18374_CR8","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1148\/rg.352140164","volume":"35","author":"MS Hofman","year":"2015","unstructured":"Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35(2):500\u201316.","journal-title":"Radiographics."},{"issue":"6","key":"18374_CR9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","volume":"46","author":"JR Howe","year":"2017","unstructured":"Howe JR, Cardona K, Fraker DL, et al. The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017;46(6):715\u201331.","journal-title":"Pancreas."},{"issue":"2","key":"18374_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.soc.2019.11.006","volume":"29","author":"AT Scott","year":"2020","unstructured":"Scott AT, Howe JR. Management of small bowel neuroendocrine tumors. Surg Oncol Clin N Am. 2020;29(2):223\u201341.","journal-title":"Surg Oncol Clin N Am."},{"issue":"6","key":"18374_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/jso.23399","volume":"108","author":"JT Au","year":"2013","unstructured":"Au JT, Levine J, Aytaman A, Weber T, Serafini F. Management of peritoneal metastasis from neuroendocrine tumors. J Surg Oncol. 2013;108(6):385\u20136.","journal-title":"J Surg Oncol."},{"issue":"4","key":"18374_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000286700","volume":"91","author":"R Kianmanesh","year":"2010","unstructured":"Kianmanesh R, Ruszniewski P, Rindi G, et al. ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. Neuroendocrinology. 2010;91(4):333\u201340.","journal-title":"Neuroendocrinology."},{"issue":"3","key":"18374_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.path.2020.04.002","volume":"13","author":"RS Gonzalez","year":"2020","unstructured":"Gonzalez RS. Diagnosis and management of gastrointestinal neuroendocrine neoplasms. Surg Pathol Clin. 2020;13(3):377\u201397.","journal-title":"Surg Pathol Clin."},{"issue":"2","key":"18374_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/jso.26285","volume":"123","author":"RK Schmocker","year":"2021","unstructured":"Schmocker RK, Wright MJ, Ding D, et al. Duodenal, ampullary, and pancreatic neuroendocrine tumors: oncologic outcomes are driven by tumor biology and tissue of origin. J Surg Oncol. 2021;123(2):416\u201324.","journal-title":"J Surg Oncol."},{"issue":"2","key":"18374_CR15","first-page":"124","volume":"41","author":"FN Gilly","year":"1994","unstructured":"Gilly FN, Carry PY, Sayag AC, et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology. 1994;41(2):124\u20139.","journal-title":"Hepatogastroenterology."},{"issue":"2","key":"18374_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Euro J Cancer. 2009;45(2):228\u201347.","journal-title":"Euro J Cancer."},{"issue":"2","key":"18374_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313.","journal-title":"Ann Surg."},{"issue":"2","key":"18374_CR18","doi-asserted-by":"publisher","first-page":"oyae343","DOI":"10.1093\/oncolo\/oyae343","volume":"30","author":"M del Olmo-Garc\u00eda","year":"2025","unstructured":"del Olmo-Garc\u00eda M, Hernandez-Rienda L, Garcia-Carbonero R, Hernando J, Custodio A, Anton-Pascual B, Gomez M, Palma Milla S, Suarez L, Bellver M, Alonso V. Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study. The Oncologist. 2025;30(2):oyae343.","journal-title":"The Oncologist."},{"issue":"8","key":"18374_CR19","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1245\/s10434-016-5734-x","volume":"24","author":"A Madani","year":"2017","unstructured":"Madani A, Thomassen I, van Gestel Y, et al. Peritoneal metastases from gastroenteropancreatic neuroendocrine tumors: incidence, risk factors and prognosis. Ann Surg Oncol. 2017;24(8):2199\u2013205.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"18374_CR20","first-page":"1","volume":"4","author":"S Das","year":"2019","unstructured":"Das S, Shi C, Koyama T, et al. Peritoneal carcinomatosis in well-differentiated small-intestinal neuroendocrine tumors with mesenteric tumor deposits. J Med Surg Pathol. 2019;4(1):1\u201310.","journal-title":"J Med Surg Pathol."},{"key":"18374_CR21","doi-asserted-by":"crossref","unstructured":"Lawlor A, Wylde H, El Asmar ML, et al. Impact of sex and deprivation on neuroendocrine tumour survival: challenges of heterogeneous data. Neuroendocrinology. 2025:1-28.","DOI":"10.1159\/000546128"},{"key":"18374_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jss.2024.07.012","volume":"302","author":"J Chang","year":"2024","unstructured":"Chang J, Suraju MO, Tran CG, et al. Association between female sex and better survival in gastroenteropancreatic neuroendocrine tumors. J Surg Res. 2024;302:53\u201363.","journal-title":"J Surg Res."},{"issue":"12","key":"18374_CR23","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3390\/diagnostics14121289","volume":"14","author":"M Franchina","year":"2024","unstructured":"Franchina M, Cavalcoli F, Falco O, La Milia M, Elvevi A, Massironi S. Biochemical markers for neuroendocrine tumors: traditional circulating markers and recent development\u2013a comprehensive review. Diagnostics. 2024;14(12):1289.","journal-title":"Diagnostics."},{"issue":"2\u20133","key":"18374_CR24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000369818","volume":"100","author":"S Massironi","year":"2014","unstructured":"Massironi S, Rossi RE, Casazza G, et al. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Neuroendocrinology. 2014;100(2\u20133):240\u20139.","journal-title":"Neuroendocrinology."},{"issue":"2","key":"18374_CR25","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1245\/s10434-006-9148-z","volume":"14","author":"EH Jensen","year":"2007","unstructured":"Jensen EH, Kvols L, McLoughlin JM, et al. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann Surg Oncol. 2007;14(2):780\u20135.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"18374_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000335587","volume":"95","author":"M Falconi","year":"2012","unstructured":"Falconi M, Bartsch DK, Eriksson B, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95(2):120\u201334.","journal-title":"Neuroendocrinology."},{"issue":"9","key":"18374_CR27","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1245\/s10434-014-3728-0","volume":"21","author":"SK Sherman","year":"2014","unstructured":"Sherman SK, Maxwell JE, O\u2019Dorisio MS, O\u2019Dorisio TM, Howe JR. Pancreastatin predicts survival in neuroendocrine tumors. Ann Surg Oncol. 2014;21(9):2971\u201380.","journal-title":"Ann Surg Oncol."},{"key":"18374_CR28","unstructured":"Network NCC. Neuroendocrine and Adrenal Tumors. 2025; Version 1.2025 \u2014 March 27, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf."},{"key":"18374_CR29","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.5114\/pjr.2023.125027","volume":"88","author":"MA Szadkowska","year":"2023","unstructured":"Szadkowska MA, Palucki J, Cieszanowski A. Diagnosis and treatment of peritoneal carcinomatosis\u2013a comprehensive overview. Pol J Radiol. 2023;88:e89\u201397.","journal-title":"Pol J Radiol."},{"issue":"1","key":"18374_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5334\/jbsr.2921","volume":"107","author":"S Kose","year":"2023","unstructured":"Kose S. Role of computed tomography in the evaluation of peritoneal carcinomatosis. J Belg Soc Radiol. 2023;107(1):27.","journal-title":"J Belg Soc Radiol."},{"issue":"8","key":"18374_CR31","doi-asserted-by":"publisher","first-page":"e13396","DOI":"10.1111\/jne.13396","volume":"36","author":"H Ohlsson","year":"2024","unstructured":"Ohlsson H, Spaak E, Galne A, Sundlov A, Almquist M. Optimal follow-up with somatostatin receptor PET\/CT imaging in patients with small intestinal neuroendocrine tumours. J Neuroendocrinol. 2024;36(8):e13396.","journal-title":"J Neuroendocrinol."},{"issue":"4","key":"18374_CR32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/PAS.0000000000001225","volume":"43","author":"MF Wright","year":"2019","unstructured":"Wright MF, Cates J, Gonzalez RS, Das S, Berlin JD, Shi C. Impact of peritoneal metastasis on survival of patients with small intestinal neuroendocrine tumor. Am J Surg Pathol. 2019;43(4):559\u201363.","journal-title":"Am J Surg Pathol."},{"issue":"6","key":"18374_CR33","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00268-011-1296-z","volume":"36","author":"O Norlen","year":"2012","unstructured":"Norlen O, Stalberg P, Oberg K, et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg. 2012;36(6):1419\u201331.","journal-title":"World J Surg."},{"issue":"6","key":"18374_CR34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1159\/000509220","volume":"111","author":"L Benhaim","year":"2021","unstructured":"Benhaim L, Faron M, Hadoux J, et al. Long-term results after surgical resection of peritoneal metastasis from neuroendocrine tumors. Neuroendocrinology. 2021;111(6):599\u2013608.","journal-title":"Neuroendocrinology."},{"issue":"1","key":"18374_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2967\/jnumed.120.242875","volume":"62","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Al-Toubah T, Pelle E, et al. Risk of bowel obstruction in patients with mesenteric or peritoneal disease receiving peptide receptor radionuclide therapy. J Nucl Med. 2021;62(1):69\u201372.","journal-title":"J Nucl Med."},{"issue":"9","key":"18374_CR36","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.2967\/jnumed.121.262048","volume":"62","author":"CE Wee","year":"2021","unstructured":"Wee CE, Dundar A, Eiring RA, et al. Bowel obstruction as a complication of peptide receptor radionuclide therapy. J Nucl Med. 2021;62(9):1320.","journal-title":"J Nucl Med."},{"issue":"6","key":"18374_CR37","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1159\/000503144","volume":"110","author":"E Merola","year":"2020","unstructured":"Merola E, Prasad V, Pascher A, et al. Peritoneal carcinomatosis in gastro-entero-pancreatic neuroendocrine neoplasms: clinical impact and effectiveness of the available therapeutic options. Neuroendocrinology. 2020;110(6):517\u201324.","journal-title":"Neuroendocrinology."},{"issue":"1","key":"18374_CR38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.surg.2013.05.030","volume":"155","author":"D Elias","year":"2014","unstructured":"Elias D, David A, Sourrouille I, et al. Neuroendocrine carcinomas: optimal surgery of peritoneal metastases (and associated intra-abdominal metastases). Surgery. 2014;155(1):5\u201312.","journal-title":"Surgery."},{"issue":"7","key":"18374_CR39","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.ejso.2022.03.019","volume":"48","author":"R Hajjar","year":"2022","unstructured":"Hajjar R, Mercier F, Passot G, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis. Eur J Surg Oncol. 2022;48(7):1626\u201330.","journal-title":"Eur J Surg Oncol."},{"issue":"6","key":"18374_CR40","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1245\/s10434-020-08321-z","volume":"27","author":"Chicago Consensus Working Group","year":"2020","unstructured":"Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: management of neuroendocrine tumors. Ann Surg Oncol. 2020;27(6):1788\u201392.","journal-title":"Ann Surg Oncol."},{"key":"18374_CR41","doi-asserted-by":"publisher","unstructured":"Su DG, Brown LM, Bansal VV, et al. Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms. Ann Surg Oncol. 2025. Online ahead of print. https:\/\/doi.org\/10.1245\/s10434-025-17360-3","DOI":"10.1245\/s10434-025-17360-3"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18374-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18374-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18374-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:08:52Z","timestamp":1765289332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18374-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["18374"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18374-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}